Literature DB >> 911603

Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain.

P L Morselli, A Baruzzi, M Gerna, L Bossi, M Porta.   

Abstract

1 Carbamazepine (CBZ) brain and plasma concentrations were measured in twenty-one patients undergoing brain surgery for tumour removal. The drug was administered prophylactically at doses ranging from 6.9 to 14.8 mg/kg for 4-5 days before the intervention. 2 In seventeen cases where sample were collected 10-14 h after dosing, CBZ brain levels ranged from 2.2-14.5 microgram/g. A significant linear relationship (p less than 0.01) was observed between brain and plasma concentrations with a brain/plasma ratio of 1.1 +/- 0.1. 3 Carbamazepine 10,11-epoxide (CBZ-Epox), present in all samples, could be quantified in three brain specimens. Its brain concentrations ranged from 1.5-2.7 microgram/g with a brain/plasma ratio of 1.1-1.2. 4 Parieto-occipital areas tended to show higher CBZ concentrations while lower values were found in temporal regions. Very low CBZ levels were found in two gliomas while in meningiomas CBZ levels were similar to those observed in normal tissue. 5 The data, showing a linear relationship between brain and plasma concentrations of both CBZ and its epoxide, give additional significance to the plasma level monitoring of antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911603      PMCID: PMC1429158          DOI: 10.1111/j.1365-2125.1977.tb00782.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  [Epilepsy following neurosurgery].

Authors:  H TERZIAN
Journal:  Rass Neurol Veg       Date:  1954-12

2.  Seizures following surgical treatment of intracranial abscesses; a clinical and electroencephalographic study.

Authors:  G B NORTHCROFT; B D WYKE
Journal:  J Neurosurg       Date:  1957-05       Impact factor: 5.115

3.  Carbamazepine as an anticonvulsant: a pilot study.

Authors:  A S Troupin; J R Green; R H Levy
Journal:  Neurology       Date:  1974-09       Impact factor: 9.910

4.  Brain and serum concentrations of diazepam in experimental epilepsy.

Authors:  G G Celesia; H E Booker; S Sato
Journal:  Epilepsia       Date:  1974-09       Impact factor: 5.864

5.  Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital.

Authors:  F Vajda; F M Williams; S Davidson; M A Falconer; A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

6.  A survey of attitudes toward the pharmacological prophylaxis of posttraumatic epilepsy.

Authors:  R L Rapport; J K Penry
Journal:  J Neurosurg       Date:  1973-02       Impact factor: 5.115

7.  Carbamazepine plasma and tissue levels in the rat.

Authors:  P L Morselli; M Gerna; S Garattini
Journal:  Biochem Pharmacol       Date:  1971-08       Impact factor: 5.858

8.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

9.  The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study.

Authors:  E A Rodin; C S Rim; P M Rennick
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

10.  Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients.

Authors:  G W Houghton; A Richens; P A Toseland; S Davidson
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

View more
  10 in total

Review 1.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 2.  Disposition of anticonvulsants in childhood.

Authors:  J I Morrow; A Richens
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 3.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

5.  Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

Authors:  M L Friis; J Christiansen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Differences between the concentrations of antiepileptic drugs in normal and pathological human brain.

Authors:  V A Sironi; L Ravagnati; G Ettorre; G P Cabrini; F Marossero
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

9.  Induction effect of phenobarbital on carbamazepine-10,11-epoxide kinetics in the rhesus monkey.

Authors:  P J Wedlund; I H Patel; R H Levy
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

10.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.